FDA Contract Explores Quantified Risk/Benefit Approach
This article was originally published in The Tan Sheet
Executive Summary
FDA is exploring the idea of a more formal, quantitative system for assessing the risk/benefit of drugs
You may also be interested in...
FDA Drug Review, Surveillance Offices To Share Authority Over Safety
FDA's drug review and drug safety offices set aside their differences in an agreement to more equally divide regulatory authority on drug safety issues
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a Sept. 22 final report
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter